155 related articles for article (PubMed ID: 36566163)
1. Preclinical evaluation of an investigational 21-valent pneumococcal conjugate vaccine, V116, in adult-rhesus monkey, rabbit, and mouse models.
Curry S; Kaufhold RM; Monslow MA; Zhang Y; McGuinness D; Kim E; Nawrocki DK; McHugh PM; Briggs ML; Smith WJ; He J; Joyce JG; Skinner JM
Vaccine; 2023 Jan; 41(4):903-913. PubMed ID: 36566163
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cross-protection between S. Pneumoniae serotypes 35B and 29 in a mouse model.
Kim E; He J; Kaufhold RM; McGuinness D; McHugh P; Nawrocki D; Xie J; Skinner JM
Vaccine; 2023 Mar; 41(11):1774-1777. PubMed ID: 36781335
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice.
McGuinness D; Kaufhold RM; McHugh PM; Winters MA; Smith WJ; Giovarelli C; He J; Zhang Y; Musey L; Skinner JM
Vaccine; 2021 Jul; 39(30):4231-4237. PubMed ID: 34074546
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
Skinner JM; Indrawati L; Cannon J; Blue J; Winters M; Macnair J; Pujar N; Manger W; Zhang Y; Antonello J; Shiver J; Caulfield M; Heinrichs JH
Vaccine; 2011 Nov; 29(48):8870-6. PubMed ID: 21964055
[TBL] [Abstract][Full Text] [Related]
6. The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C.
Shi Y; Nolan KM; Burton RL; Shekar T; Murphy RD; Banniettis N; Musey L; Buchwald UK
Hum Vaccin Immunother; 2023 Aug; 19(2):2235238. PubMed ID: 37529944
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of antimicrobial resistance in non-vaccine serotypes of non-invasive/colonization isolates of Streptococcus pneumoniae: A cross-sectional study eight years after the licensure of conjugate vaccine in Japan.
Kawaguchiya M; Urushibara N; Aung MS; Ito M; Takahashi A; Habadera S; Kobayashi N
J Infect Public Health; 2020 Aug; 13(8):1094-1100. PubMed ID: 32446777
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants.
Xie J; Zhang Y; Caro-Aguilar I; Indrawati L; Smith WJ; Giovarelli C; Winters MA; MacNair J; He J; Abeygunawardana C; Musey L; Kosinski M; Skinner JM
Pediatr Infect Dis J; 2020 Jan; 39(1):70-77. PubMed ID: 31725555
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study.
Haranaka M; Yono M; Kishino H; Igarashi R; Oshima N; Sawata M; Platt HL
Hum Vaccin Immunother; 2023 Aug; 19(2):2228162. PubMed ID: 37389808
[TBL] [Abstract][Full Text] [Related]
11. Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A.
Hao L; Kuttel MM; Ravenscroft N; Thompson A; Prasad AK; Gangolli S; Tan C; Cooper D; Watson W; Liberator P; Pride MW; Jansen KU; Anderson AS; Scully IL
Vaccine; 2022 Aug; 40(33):4872-4880. PubMed ID: 35810060
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain.
Caro-Aguilar I; Indrawati L; Kaufhold RM; Gaunt C; Zhang Y; Nawrocki DK; Giovarelli C; Winters MA; Smith WJ; Heinrichs J; Skinner JM
Vaccine; 2017 Feb; 35(6):865-872. PubMed ID: 28087148
[TBL] [Abstract][Full Text] [Related]
13. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.
Cooper D; Yu X; Sidhu M; Nahm MH; Fernsten P; Jansen KU
Vaccine; 2011 Sep; 29(41):7207-11. PubMed ID: 21689707
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
Mohapi L; Pinedo Y; Osiyemi O; Supparatpinyo K; Ratanasuwan W; Molina JM; Dagan R; Tamms G; Sterling T; Zhang Y; Pedley A; Hartzel J; Kan Y; Hurtado K; Musey L; Simon JK; Buchwald UK;
AIDS; 2022 Mar; 36(3):373-382. PubMed ID: 34750291
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age.
Essink B; Peterson J; Yacisin K; Lal H; Mirza S; Xu X; Scully IL; Scott DA; Gruber WC; Jansen KU; Watson W
Hum Vaccin Immunother; 2021 Aug; 17(8):2691-2699. PubMed ID: 33661716
[TBL] [Abstract][Full Text] [Related]
16. Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.
Hammitt LL; Quinn D; Janczewska E; Pasquel FJ; Tytus R; Reddy KR; Abarca K; Khaertynova IM; Dagan R; Dawson R; McCauley J; Shekar T; Fu W; Pedley A; Sterling T; Tamms G; Musey L; Buchwald UK
Hum Vaccin Immunother; 2023 Dec; 19(1):2177066. PubMed ID: 36864601
[TBL] [Abstract][Full Text] [Related]
17. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK
Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861
[TBL] [Abstract][Full Text] [Related]
18. A Nonadjuvanted Whole-Inactivated Pneumococcal Vaccine Induces Multiserotype Opsonophagocytic Responses Mediated by Noncapsule-Specific Antibodies.
David SC; Brazel EB; Singleton EV; Minhas V; Laan Z; Scougall C; Chen AY; Wang H; Gates CJ; McLean KT; Brown JS; Ercoli G; Higgins RA; Licciardi PV; Mulholland K; Davies JB; Hirst TR; Paton JC; Alsharifi M
mBio; 2022 Oct; 13(5):e0236722. PubMed ID: 36125268
[TBL] [Abstract][Full Text] [Related]
19. Validation of a Multiplexed Opsonophagocytic Assay for 11 Additional Pneumococcal Serotypes and Its Application to Functional Antibody Evaluation Induced by Pneumococcal Polysaccharide Vaccine.
Cha J; Kim HW; Lee JH; Lee S; Kim KH
J Korean Med Sci; 2018 Dec; 33(51):e340. PubMed ID: 30546285
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
